ArticleEClinicalMedicine2025

Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial.

Armin Ghobadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.